XOMA Corporation

09/04/2024 | Press release | Distributed by Public on 09/04/2024 07:18

XOMA Royalty to Present at Upcoming Investor Conferences in September

XOMA Royalty to Present at Upcoming Investor Conferences in September

Download as PDFSeptember 04, 2024 7:30am EDT

EMERYVILLE, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the following September 2024 investor conferences:

  • H.C. Wainwright 26th Annual Global Investment Conference taking place September 9-11, 2024, in New York, NY. Owen Hughes, Chief Executive Officer, and Brad Sitko, Chief Investment Officer, will present a corporate overview on Monday, September 9, 2024, at 9:00 AM ET. The presentation can be accessed at https://bit.ly/4coqH9K.
  • 2024 Cantor Global Healthcare Conference, which is being held September 17-19, 2024, in New York, NY. Mr. Hughes and Mr. Sitko will present a corporate overview on September 17, 2024, at 2:30 PM ET. The presentation can be accessed at https://bit.ly/3yNkp5U.

XOMA's presentations can also be accessed by visiting the investor relations section of the Company's website at www.xoma.com. A replay of each presentation will be available and archived on the site for 90 days after the event.

About XOMA Royalty Corporation
XOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA Royalty acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA Royalty acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio of assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit www.xoma.com or follow XOMA Royalty Corporation on LinkedIn.

XOMA Investor Contact
Juliane Snowden
XOMA Royalty
+1 646-438-9754
[email protected]
XOMA Media Contact
Kathy Vincent
KV Consulting & Management
+1 310-403-8951
[email protected]

Source: XOMA Corporation

Released September 4, 2024